Composition, pharmaceutical composition, use of a stable topical composition comprising a nanoemulsion and of at least one antileishmanial compound, and method for the treatment of cutaneous leishmaniasis
US-2024016826-A1 · Jan 18, 2024 · US
Small molecule AMPK activators
US11040935B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-11040935-B2 |
| Application number | US-201716339534-A |
| Country | US |
| Kind code | B2 |
| Filing date | Oct 4, 2017 |
| Priority date | Oct 5, 2016 |
| Publication date | Jun 22, 2021 |
| Grant date | Jun 22, 2021 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
Described herein are compounds that disrupt the interaction between Fbxo48 and phosphorylated-AMPK.
First claim
Opening claim text (preview).
What is claimed is: 1. A compound selected from the group consisting of: or a pharmaceutically acceptable salt thereof. 2. The compound of claim 1 , wherein the compound is: or a pharmaceutically acceptable salt thereof. 3. The compound of claim 1 , wherein the compound is: or a pharmaceutically acceptable salt thereof. 4. A compound of formula: or a pharmaceutically acceptable salt thereof.
Assignees
Inventors
Classifications
- A61K31/133Primary
having hydroxy groups, e.g. sphingosine · CPC title
Nitrogen atoms · CPC title
with hydrocarbon or substituted hydrocarbon radicals attached to the ring nitrogen atom · CPC title
having no double bonds between ring members or between ring members and non-ring members · CPC title
- C07C217/34Primary
by halogen atoms, by trihalomethyl, nitro or nitroso groups, or by singly-bound oxygen atoms · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US11040935B2 cover?
- Described herein are compounds that disrupt the interaction between Fbxo48 and phosphorylated-AMPK.
- Who is the assignee on this patent?
- Univ Of Pittsburgh—Of The Commonwealth System Of Higher Education, The United States As Represented By The Dept Of Veterans Affairs
- What technology area does this patent fall under?
- Primary CPC classification A61K31/133. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Tue Jun 22 2021 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).